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Abstract
Single nucleotide polymorphisms (SNPs) may modulate individual susceptibility 
to carcinogens. We designed a genome-wide association study to characterize 
individuals presenting extreme phenotypes of high and low risk to develop 
tobacco- induced non-small cell lung cancer (NSCLC), and we validated our 
results. We hypothesized that this strategy would enrich the frequencies of the 
alleles that contribute to the observed traits. We genotyped 2.37 million SNPs 
in 95 extreme phenotype individuals, that is: heavy smokers that either developed 
NSCLC at an early age (extreme cases); or did not present NSCLC at an ad-
vanced age (extreme controls), selected from a discovery set (n = 3631). We 
validated significant SNPs in 133 additional subjects with extreme phenotypes 
selected from databases including >39,000 individuals. Two SNPs were validated: 
rs12660420 (pcombined = 5.66 × 10
−5; ORcombined = 2.80), mapping to a noncoding 
transcript exon of PDE10A; and rs6835978 (pcombined = 1.02 × 10
−4; ORcom-
bined = 2.57), an intronic variant in ATP10D. We assessed the relevance of both 
proteins in early- stage NSCLC. PDE10A and ATP10D mRNA expressions cor-
related with survival in 821 stage I–II NSCLC patients (p = 0.01 and p < 0.0001). 
PDE10A protein expression correlated with survival in 149 patients with stage 
I–II NSCLC (p = 0.002). In conclusion, we validated two variants associated 
with extreme phenotypes of high and low risk of developing tobacco- induced 
NSCLC. Our findings may allow to identify individuals presenting high and 
low risk to develop tobacco- induced NSCLC and to characterize molecular 
mechanisms of carcinogenesis and resistance to develop NSCLC.
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Introduction
In the recent years, genetic susceptibility to lung cancer 
has been explored by many genome-wide association stud-
ies (GWAS), which have reported several genomic loci 
and candidate genes that exert moderate effects on lung 
cancer risk. The most well- known loci and genes identi-
fied are the CHRNA3 and CHRNA5 subunits of the α7 
nicotinic acetylcholine receptor (nAChR), located on the 
15q25 region [1–3]; TERT and CLPTM1L [4–7], which 
are closely located at 5p15.33; BAT3, mapped to 6p21.23 
[8]; and GPC5 at 13q31.3 [9]. Most of these studies fol-
low a random sampling design, including smoking habits 
as a covariate. Several noteworthy associations are found 
exclusively in subgroups of subjects defined upon their 
smoking habits. For example, the 15q25 locus is associ-
ated with lung cancer in former and current smokers, 
while the 13q31 locus is associated with susceptibility to 
lung cancer in never smokers [7, 9].
However, despite tobacco smoke being the most relevant 
known risk factor for lung cancer, no association studies 
have analyzed the individual risk that it confers through 
the study of subjects presenting extreme phenotypes of high 
and low risk to develop non- small- cell lung cancer (NSCLC) 
induced by tobacco. Such designs may help to identify high- 
risk populations that could benefit from prevention and 
screening programs and to identify the molecular mechanisms 
that underlie such clinically relevant phenotypes.
We conducted a GWAS applying an extreme phenotype 
sampling in heavy smokers presenting high and low risk of 
developing NSCLC, and we validated our results using the 
same approach. We selected individuals who developed 
tobacco- induced NSCLC at early onset and healthy subjects 
who did not develop NSCLC at an advanced age, despite 
having a long smoking history. We aimed to identify new 




We performed a two- stage extreme phenotype study to 
increase the efficiency of discovering single nucleotide 
polymorphisms (SNPs) associated with the risk of devel-
oping tobacco- induced NSCLC. We hypothesized that risk 
Figure 1. Study design. From our series, we selected the individuals presenting extreme phenotypes of high and low risk of developing NSCLC 
induced by tobacco. Heavy smokers that either developed NSCLC at an early age were selected as extreme cases, and individuals that did not develop 
NSCLC at an advanced age, despite heavy tobacco consumption, were selected as extreme controls. The specific thresholds to define these populations 
were set to select the most extreme phenotypes in our series. *We included selected cases that developed NSCLC at extremely young ages but 
presented tobacco consumption <15 pack- years, given their phenotypic relevance and because we assumed that they were too young to achieve the 
threshold of smoke consumption.
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alleles would be strongly enriched in the phenotypic 
extremes, and therefore, a limited number of carefully 
selected individuals with extreme phenotypes might be 
sufficient to identify novel candidate genes and/or alleles 
[10].
We enrolled subjects into a discovery and a validation 
set (Fig. 1). The cancer cohort subjects (extreme cases) 
were selected from heavy smokers (≥15 packs- years) with 
histologically confirmed diagnosis of NSCLC at an early 
age (≤55 years). In the validation series, we included 
selected cases that developed NSCLC at extremely young 
ages but presented tobacco consumption <15 packs- years, 
given their phenotypic relevance and because we assumed 
that they were too young to achieve the threshold of 
smoke consumption. We also included some borderline 
cases for age (≤56 years). The cancer- free cohort individu-
als (extreme controls) were selected from heavy smokers 
(≥15 packs- years) that had not developed NSCLC or any 
other type of cancer at an advanced age (≥72 years). The 
thresholds for tobacco consumption and age were set with 
the aim to select from our series the individuals present-
ing the most extreme phenotypes regarding individual risk 
of developing NSCLC induced by tobacco.
The discovery set was recruited among 3631 patients 
included in the databases of the University Clinic of 
Navarra (Pamplona, Spain), Center for Applied Medical 
Research (CIMA, Pamplona, Spain), and Hospital 
Universitario Nuestra Señora de La Candelaria (Tenerife, 
Spain).
The independent validation set was recruited from the 
Spanish branch of the European Prospective Investigation 
in Cancer (EPIC) Project (www.epic-spain.com), which 
includes genomic DNA samples and clinical data from 
39,880 individuals, and from additional new cases from 
the University Clinic of Navarra.
Samples and data from patients were processed follow-
ing standard operating procedures approved by the respec-
tive Ethical and Scientific Committees. All patients gave 
written informed consent to allow the use of their biological 
samples and clinical data for research purposes. The study 
protocol was approved by the Ethics Committee of the 
University Clinic of Navarra.
DNA genotyping
Genomic DNA was obtained from peripheral blood mono-
nuclear cells using the QIAamp DNA Mini Kit (Qiagen 
Iberia, Madrid, Spain) according to the manufacturer’s 
instructions and stored at −20°C until use. Genotyping 
in the discovery set was performed using the Illumina 
HumanOmni2.5- Quad BeadChip according to the manu-
facturer’s protocols (Illumina, San Diego, CA, USA). 
Genotyping in the validation set was performed using the 
Infinium assay following the manufacturer’s instructions 
(Illumina).
Statistical analysis
Discovery and validation analyses, per-allele odds ratios 
(OR), and standard errors were estimated for each SNP 
using a multivariate logistic regression model, adjusting 
for sex. The covariates age and tobacco consumption were 
used for the design, and therefore, they were not included 
in the statistical analysis.
Genotype clustering and calling were carried out using 
GenTrain v2.0 in GenomeStudio v2011.1 (Illumina). 
Samples were excluded from further analyses if they had 
more than 2% missing genotype data SNPs with a call 
rate<0.95 or deviated from the Hardy–Weinberg equilib-
rium (HWE) (p- value ≤1 × 10−5) were also excluded. 
From the discovery analysis, SNPs with a p- value ≤5 × 10−4 
and minor allele frequency (MAF) > 5% in the single 
SNP analysis were selected for validation. When two SNPs 
presented a very high correlation (r2 > 0.8), they were 
considered redundant, and only the one that presented 
the highest Illumina score was selected.
Genomic imputation
To find map causing variants, data imputation for the 
untyped SNPs at all the validated SNPs was performed 
using IMPUTE v2.3.2 [11] for samples from the discovery 
set using phased haplotypes from the 1000 Genomes Phase 
3 (b37) panel as reference [12]. Those imputed genotypes 
with scores >0.3 were tested for association.
Table 1. Characteristics of patients.









N 47 48 78 55
Sex M/F 31/16 43/5 52/26 51/4
(%M/%F) (66/34) (89.4/10.6) (66.7/33.3) (92.7/7.3)
Mean age, years 49 76 49 77
(range) (38–55) (72–84) (35–56) (72–85)
Mean tobacco 
consumption,
41 69.4 38 48
packs- year (range) (15–99) (40–150) (4–101) (16–123)
Histological subtypes
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Assessment of the prognostic value of 
mRNA expression and protein expression of 
target genes
We attempted to validate the functional relevance of the 
genes associated with the validated SNPs in NSCLC, assess-
ing the expression of the related mRNA and proteins in 
patients with early- stage NSCLC. We correlated the tran-
scriptomic data of ATP10D and PDE10A with recurrence- free 
survival (RFS) and overall survival (OS) using the KM- Plotter 
application [13] in patients with early- stage NSCLC. The 
database used (http://kmplot.com) includes gene expression 
data and survival information on 821 patients with stage 
I–II NSCLC, downloaded from the Cancer Biomedical 
Informatics Grid (CaBIG), the Gene Expression Omnibus 
(GEO), and the Cancer Genome Atlas (TCGA). Survival 
curves were estimated using Kaplan–Meier curves. Significant 
differences between groups were tested using the log- rank 
test. RFS and OS were calculated respectively from the date 
of surgery to the date of recurrence or death.
We assessed the prognostic value of PDE10A protein 
expression in tumor samples from 149 patients with 
stage I–II NSCLC resected at University Clinic of Navarra. 
PDE10A immunohistochemical assay and staining scores 
established by semiquantitative analysis were performed 
as previously described [14]. We used an anti- human 
PDE10A antibody (Genetex) diluted 1:500. The specific-
ity of PDE10A antibody was demonstrated by Western 
blot analysis and immunocytochemistry of cell lines 
expressing different levels of the protein. Isotype and 
negative (omission of the primary antibody) controls 
were performed [14].
The univariate and multivariate Cox proportional haz-
ards modeling were used to determine the effects of vari-
ables on cancer- specific OS and RFS. Variables with p < 0.1 
in the univariate analysis were included in the multivariable 
analysis. The proportional hazards assumption was exam-
ined by testing interactions between the covariables of 
the final model and time. Statistical analysis was performed 
using SPSS 15.0 (Chicago, Ill., USA) and Stata12 (College 
Station, TX: USA).
Results
Identification and validation of SNPs related 
to individuals presenting extreme 
phenotypes of developing NSCLC induced by 
tobacco
We analyzed 228 individuals with extreme phenotypes, 
95 in the discovery set and 133 in the validation set 
(Table 1). The discovery set included 47 extreme cases 
that developed NSCLC at an early age (mean: 49 years) 
and were heavy smokers (mean: 41 packs- years). Extreme 
controls were 48 individuals that did not develop NSCLC 
at an advanced age (mean: 76 years) despite high tobacco 
consumption (mean: 69 packs- years). One control from 
the discovery set was excluded due to low call rate 
(call rate <0.98). The validation set included 78 extreme 
cases (mean age: 49 years; and 38 packs- years) and 55 
extreme controls (mean age: 77 years; and 48 
packs- years).
We successfully genotyped 2,379,855 variants in the discovery 
set, and 61,061 were excluded from the analysis due to low 
genotyping call-rate (0.95), and 370 were deviated from HWE 
in controls, leaving 2,318,553 for further analysis. Thirty- six 
SNPs presenting high association in the GWAS (p < 5 × 10−4, 
Table S1) were analyzed in the validation set.
Two SNPs were successfully replicated in the valida-
tion set (Table 2). The strongest validated association 
was with SNP rs12660420 at the 6q27 locus (combined 
p = 5.66 × 10−5; combined OR = 2.80, 95% CI: 1.69–
4.61), which maps to a non-coding transcript of the 
PDE10A gene. This SNP tags a linkage disequilibrium 
(LD) block of 85.8Kb in chromosome 6 (coordinates 
166,109,230–166,195,063) (NCBI build 37 assembly), as 
defined by the furthest upstream and downstream SNPs 
displaying a detectable correlation (r2 > 0.20) with 
rs12660420.
Subsequently, genotypes of all other known variants 
in the locus with minor allele frequency >5% were 
imputed to this locus. In total, 275 SNPs were reliably 
imputed (imputation r2 score>0.3) and analyzed but 
Table 2. Single nucleotide polymorphisms validated in extreme cases versus extreme controls.
SNPs Chromosome Position References Alternate Study p- value MAF OR 95% CI
rs12660420 6 166193932 C T Discovery 1.48E- 04 0.28 5.29 2.24–12.51
Validation 0.04805 0.32 1.88 1.01–3.5
Combined 5.66E- 05 0.31 2.80 1.69–4.61
rs6835978 4 47500814 A G Discovery 3.69E- 04 0.24 5.15 2.09–12.7
Validation 0.04303 0.32 1.80 1.02–3.19
Combined 1.02E- 04 0.31 2.57 1.6–4.1
CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphisms.
Associations between SNPs and NSCLC risk were assessed by logistic regression analyses adjusted for sex. Additive model of inheritance was considered. 
ORs are per copy of the specified minor allele. Chromosome positions are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19).
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none showed a lower p- value than rs12660420. The LD 
plot showing the p- values of these SNPs is shown in 
Figure 2. The related gene, PDE10A, encodes a protein 
that belongs to the cyclic nucleotide phosphodiesterase 
family. PDE10A expression correlates with lung cancer 
prognosis, and its pharmacological inhibition suppresses 
growth of NSCLC cell lines [15], so it seems a plausible 
candidate gene for lung cancer risk. Although the vali-
dated SNP lies in a non-coding transcript of the PDE10A 
gene, genetic variation in regulatory elements may influ-
ence expression.
The second validated SNP was rs6835978 (chr4:47498797) 
in 4p12 (combined p = 1.02 × 10−4; combined OR = 2.57, 
95% IC: 1.6–4.1, Table 2), an intronic variant in the 
ATP10D gene (ATPase phospholipid transporting 10D) 
[16]. ATP10D has not previously been related to lung 
cancer or other tumors. rs6835978 tags to a LD block of 
82Kb in chromosome 4 (47,481,971–47,564,368), defined 
as described above. A total of 228 SNPs were reliably 
imputed in the region, and rs6835978 remained the most 
significantly associated SNP (along with rs12510653, in 
complete LD with it [r2 = 1]).
Figure 2. Association and recombination plot of the LD block containing the validated SNPs and ±200 kb boundaries. Plot shows the genomic region 
containing (A) rs12660420 (B) rs6835978 SNPs associated with lung cancer and the −log10 association p- values of genotyped and imputed SNPs in 
the discovery set (MAF > 5%). Circles and diamonds indicate genotyped and imputed SNPs, respectively. Recombination rates are also shown. SNP 
color indicates the strength of LD (r2) with rs12660420 (A) or rs6835978 (B). The rectangle below the plot shows the genes mapping in the region as 
well as, shaded in light blue, the LD block tagged by the associated SNPs. Recombination rates are based on the 1000 Genomes Project, and genomic 
coordinates are based on Genome Reference Consortium Human Build 37 (GRCh37/hg19). Plots were generated using LocusZoom software [31].
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Assessment of the prognostic value of 
mRNA expression and protein expression of 
target genes in patients with early- stage 
NSCLC
We evaluated the prognostic value of mRNA expression 
of PDE10A and ATP10D with the in silico tool KM- plotter 
[13] in 821 patients presenting stage I–II NSCLC. We 
analyzed PDE10A (probes 211170 and 211171) and ATP10D 
(probe 213238). We classified patients into two groups 
according to the median value of expression of each bio-
marker. Patients with higher PDE10A mRNA expression 
showed decreased OS using both probes (p = 0.011 and 
p < 0.0001; Fig. 3, panels A and B). Low mRNA expres-
sion of ATP10D was associated with shorter OS 
(p < 0.0001; Fig. 3, panel C).
We assessed the prognostic value of PDE10A protein 
expression in 149 patients with stage I–II NSCLC (Table 
S2), followed during a median period of 46.5 months 
(interquartile range: 91.6–22.0). High tumor expression 
of PDE10A correlated with decreased RFS (p = 0.0006) 
and OS (p = 0.002) (Fig. 4). PDE10A expression cor-
related significantly with RFS and OS in the univariate 
analysis (Table 3). In the multivariate analysis, PDE10A 
expression was the strongest independent prognostic fac-
tor, over stage and age, and the only one that retained 
significance for both RFS (HR = 2.637; 95% CI = 1.381–
5.036; p = 0.003) and OS (HR = 2.909; 95% CI = 1.376–
6.144; p = 0.005).
Discussion
We identified and validated two novel variants associated 
with individuals presenting extreme phenotypes of risk 
to develop NSCLC induced by tobacco. To our knowledge, 
this is the first study that uses this strategy to identify 
novel genetic variants related to NSCLC cancer risk. This 
methodology consists of studying reduced groups of indi-
viduals with very characteristic and clinically relevant 
phenotypes, thus enriching biomarker expression in the 
individuals studied, and it has allowed outstanding cancer 
biomarkers to be identified, as reviewed elsewhere [17]. 
In the discovery phase, we used the HumanOmni2.5- Quad 
BeadChip array, a high- density chip that allows genotyp-
ing of 2.5 million SNPs across the whole genome, targeting 
genetic variation down to 1% MAF. To our knowledge, 
this is the first study that assesses cancer risk using this 
powerful platform.
The strongest validated association was SNP rs12660420, 
which maps to a non-coding transcript of PDE10A. This 
gene encodes a protein that belongs to the cyclic nucleo-
tide phosphodiesterase family. Phosphodiesterases (PDE) 
represent a large superfamily of hydrolases that control 
the intracellular levels of cyclic nucleotides by hydrolyzing 
cAMP and cGMP to 5_AMP and 5_GMP and are critical 
regulators of the myriad physiological and pathophysiologi-
cal processes under cyclic nucleotide control [18]. PDE4, 
a well- known target for therapy of chronic obstructive 
pulmonary disease [19], is also expressed in lung cancer 
and promotes lung cancer progression [20]. Preclinical 
data indicate that PDE4 inhibitors have also a role in 
the treatment for EGFR- mutant NSCLC patients with high 
pretreatment levels of BIM and mTOR [21]. Li et al. 
showed that PDE10A mRNA and protein levels are over-
expressed in colon tumor cells as compared to normal 
colonocytes; that silencing PDE10A suppressed the growth 
of colon tumor cells; and that overexpression of PDE10A 
promotes growth of colonocytes and adenoma cells [22]. 
The same group recently reported that Pf- 2545920, a highly 
specific PDE10A inhibitor, inhibits colon tumor cell growth 
at concentrations that increase cGMP and cAMP levels 
and activate PKG and PKA; and that Pf- 2545920 reduces 
β- catenin- mediated transcription of survivin, resulting in 
caspase activation and apoptosis [23]. Shen et al. [15] 
have reported that PDE10A mutations are predicted to 
influence PDE10A allosteric regulation in lung adenocar-
cinoma; that high levels of PDE10A expression correlate 
with worsened lung adenocarcinoma prognosis; and that 
Pf- 2545920 also suppresses the growth of NSCLC cell 
lines. Finally, PDE10A somatic mutations have been 
described in up to 19% of prostate cancers and correlated 
with increased levels of phosphorylated C- AMP responsive 
element binding protein (p- CREB) [24]. These data sug-
gest that PDE10A might be a relevant target for cancer 
therapy and prevention.
The second validated variant, SNP rs6835978, is an 
intronic variant of ATP10D, which belongs to a subfamily 
of P- type ATPases implicated in the translocation of phos-
pholipids from the exoplasmic to the cytoplasmic leaflet 
of the cellular biological membranes. Although ATP10D 
has not previously been related to NSCLC, genetic vari-
ation in this gene has been associated with levels of plasma 
sphingolipids [25]. Bioactive sphingolipids, such as 
sphingosine- 1- phosphate (S1P), and ceramides, are signal-
ing molecules involved in the activation of pathways that 
are directly relevant to carcinogenesis [26]. Ceramide plays 
a major role in the development of chronic pulmonary 
diseases and has also been involved in lung cancer devel-
opment induced by cigarette smoke [27]. Alberg et al. 
reported that higher concentrations of S1P and total cera-
mide in plasma were associated with an increased future 
risk of lung cancer [28].
We analyzed the prognostic value of PDE10A and 
ATP10D mRNA and PDE10A protein levels in patients 
with stage I–II NSCLC. We confirmed that high and 
low mRNA expression, respectively, of PDE10A and 
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Figure 3. Correlation of the transcriptomic data of PDE10A an ATP10D with overall survival (OS) using the Kaplan–Meier Plotter application in several 
databases including 821 patients with stage I–II NSCLC. Panels A and B: OS according to PDE10A mRNA expression levels using probes 211170 (A) 
and 211171 (B). Panel C: OS according to ATP10D mRNA expression levels using probe 213238.
Figure 4. Correlation of PDE10A protein expression with overall survival (OS) and relapse- free survival (RFS) in 149 patients with stage I–II NSCLC. 
Panels A and B: representative examples of tumors presenting low (A) and high (B) PDE10A staining. Scale bar: 50 micras. Panel C: RFS according to 
PDE10A staining. Panel D: OS according to PDE10A staining.
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ATP10D significantly correlated with shorter survival. 
To our knowledge, this is the first association of ATP10D 
with cancer prognosis. We confirmed that PDE10A pro-
tein levels in stage I–II NSCLC patients correlated with 
decreased survival. The results that we obtained for 
mRNA and protein expression of PDE10A are consistent 
among them and also with previous results reported in 
NSCLC [15]. These results render PDE10A and ATP10D 
as potentially useful prognostic and therapeutic targets 
in NSCLC.
Tobacco- induced NSCLC represents one of the most 
relevant challenges to public health. Therefore, the iden-
tification of genetic factors that confer to individuals 
either an increased risk or an intrinsic protection to 
develop the disease would be of critical relevance, allow-
ing the identification of high- risk populations, in which 
tobacco cessation and screening programs may be most 
beneficial. Most importantly, it may lead to further under-
standing of mechanisms of carcinogenesis and natural 
protection against cancer, which might inspire new thera-
peutic strategies. Interestingly, even though our study was 
specifically designed for NSCLC, the individuals in the 
cancer- free cohort did not develop any other tumors. 
Therefore, our results may also relate to other neoplasms, 
especially those related to tobacco.
To our knowledge, this is the first study that defines 
and targets phenotypes of decreased risk to develop tobacco- 
induced NSCLC and that attempts to characterize the 
genetic causes of such protection. The study of these 
proficient cancer risk phenotypes (PROCARPs) may allow 
to identify the underlying protective mechanisms and may 
provide valuable targets for cancer prevention. The iden-
tification of PROCARPs is challenging, because it requires 
to distinguish individuals presenting a truly decreased 
cancer risk from others which just present absence of the 
disease (i.e., they are non-apparent phenotypes) [29]. We 
hypothesized that the selection of individuals that are 
overexposed to either extrinsic or intrinsic cancer risk 
factors and yet do not develop cancer may allow to iden-
tify and study PROCARPs [17, 30]. On the other hand, 
phenotypes of increased cancer risk (deficient cancer risk 
phenotypes, DECARPs) are apparent phenotypes that are 
readily identifiable (e.g., cancer familiar syndromes, cancer 
development at young ages, etc.) [29].
The main limitation of our study is that the sample size 
is limited due to the difficulty to enroll extreme individu-
als. This may impair to reach p- values of genome-wide 
significance. Nevertheless, to overcome this limitation, we 
explored mRNA and protein expression of PDE10A and 
ATP10D in two different patient populations of early- stage 
NSCLC, and we found very significant correlations with 
survival. Functional validation will also be required to con-
firm the relevance of our findings. Also, despite our efforts 
to recruit highly selected individuals, phenotypic heteroge-
neity may persist regarding demographical and clinical 
characteristics. Nevertheless, this limitation constitutes in 
fact the greatest opportunity to improve this strategy, through 
the application of more stringent selection criteria to identify 
more homogeneous phenotypes with regard to age, tobacco 
consumption, or other relevant variables. Our strategy may 
also be pursued using different high- throughput techniques, 
such as exome or genome sequencing or assessment of 
the transcriptome, and epigenome. Finally, additional studies 
will be required to further elucidate the optimal definitions 
of extreme phenotypes.
In summary, we identified and validated two new genetic 
variants in PDE10A and ATP10D associated with individu-
als presenting extreme phenotypes of high and low risk 
of developing tobacco- induced NSCLC, and we confirmed 
the prognostic relevance of the associated proteins in 
early- stage NSCLC. Our findings may have relevant impli-
cations to define high- risk cancer populations and to 
Table 3. Univariate and multivariate Cox regression analyses of PDE10A protein expression for recurrence- free survival (RFS) and overall survival (OS) 
in patients with stage I–II NSCLC.
Factor n
RFS OS
Univariate HR (95% 
CI) p
Multivariate HR (95% 
CI)1 p
Univariate HR (95% 
CI) p
Multivariate HR (95% 
CI)1 p
PDE10A
Low 74 – – – – – – – –
High 75 2.831 (1.501–5.340) 0.001 2.637 (1.381–5.036) 0.003 2.86 (1.371–5.970) 0.005 2.909 (1.376–6.144) 0.005
Stage
I 101 – – – – – – – –
II 48 1.742 (0.963–3.151) 0.066 1.425 (0.779–2.607) 0.250 1.971 (1.011–3.840) 0.046 1.700 (0.864–3.331) 0.125
Age
<65 74 – – – – – – – –
>65 75 1.361 (0.755–2.457) 0.305 – – 1.822 (0.927–3.579) 0.082 2.065 (1.042–4.091) 0.038
OS, overall survival; RFS, relapse- free survival.
1Adjusted by gender, stage, and age.
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characterize molecular mechanisms of carcinogenesis and 
resistance to develop cancer, thus supporting the feasibility 
of extreme phenotype selection studies in cancer research.
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